NextCure NXTC Stock
NextCure Price Chart
NextCure NXTC Financial and Trading Overview
| NextCure stock price | 3.15 USD |
| Previous Close | 6.2 USD |
| Open | 6.96 USD |
| Bid | 2.56 USD x 200 |
| Ask | 4.19 USD x 200 |
| Day's Range | 2.85 - 6.96 USD |
| 52 Week Range | 2.83 - 15.74 USD |
| Volume | 892.69K USD |
| Avg. Volume | 64.4K USD |
| Market Cap | 12.21M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -16.82 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.33 USD |
NXTC Valuation Measures
| Enterprise Value | -13655116 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.4047904 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.33908507 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.252 |
Trading Information
NextCure Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -40.57% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 15.74 USD |
| 52 Week Low | 2.83 USD |
| 50-Day Moving Average | 9.9 USD |
| 200-Day Moving Average | 9.99 USD |
NXTC Share Statistics
| Avg. Volume (3 month) | 64.4K USD |
| Avg. Daily Volume (10-Days) | 135.8K USD |
| Shares Outstanding | 3.61M |
| Float | 2.28M |
| Short Ratio | 0.97 |
| % Held by Insiders | 14.84% |
| % Held by Institutions | 62.54% |
| Shares Short | 58.02K |
| Short % of Float | 1.60% |
| Short % of Shares Outstanding | 1.60% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:12 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -66.71% |
| Return on Equity (ttm) | -132.40% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -54285000 USD |
| Net Income Avi to Common (ttm) | -54664000 USD |
| Diluted EPS (ttm) | -16.82 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 29.74M USD |
| Total Cash Per Share (mrq) | 8.23 USD |
| Total Debt (mrq) | 3.88M USD |
| Total Debt/Equity (mrq) | 14.52 USD |
| Current Ratio (mrq) | 4.606 |
| Book Value Per Share (mrq) | 9.968 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -49982000 USD |
| Levered Free Cash Flow (ttm) | -27142876 USD |
Profile of NextCure
| Country | United States |
| State | MD |
| City | Beltsville |
| Address | 9000 Virginia Manor Road |
| ZIP | 20705 |
| Phone | 240 399 4900 |
| Website | https://www.nextcure.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 40 |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Q&A For NextCure Stock
What is a current NXTC stock price?
NextCure NXTC stock price today per share is 3.15 USD.
How to purchase NextCure stock?
You can buy NXTC shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for NextCure?
The stock symbol or ticker of NextCure is NXTC.
Which industry does the NextCure company belong to?
The NextCure industry is Biotechnology.
How many shares does NextCure have in circulation?
The max supply of NextCure shares is 3.61M.
What is NextCure Price to Earnings Ratio (PE Ratio)?
NextCure PE Ratio is now.
What was NextCure earnings per share over the trailing 12 months (TTM)?
NextCure EPS is -16.82 USD over the trailing 12 months.
Which sector does the NextCure company belong to?
The NextCure sector is Healthcare.
NextCure NXTC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
- {{ link.label }} {{link}}